此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

RANK 配体抑制可对抗肌肉减少症和潜在骨质疏松症

2026年9月15日 更新者:Ronald Man Yeung WONG、Prince of Wales Hospital, Shatin, Hong Kong

RANK 配体抑制治疗伴有骨质疏松症的肌肉减少症:一项随机、双盲、双模拟、主动对照试验

The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.

研究概览

详细说明

Aims:

  1. To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
  2. To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.

研究类型

介入性

注册 (估计的)

120

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Hong Kong、中国
        • 招聘中
        • The Chinese University of Hong Kong
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 及以上 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Elderly males or females aged 65 years or older
  • diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
  • Willing and able to comply with study protocol including follow-up evaluations.

Exclusion Criteria:

  • history of recent fracture i.e., within 3 months
  • history of prior anti-osteoporotic drug
  • disease or medication affecting bone or muscle metabolism
  • Chairbound or bedbound
  • Unable to agree for consent
  • contraindication to drug i.e., Denosumab or Zoledronic Acid
  • Underlying malignancy or disease known to cause cachexia
  • severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
  • moderate to severe liver failure (Child-Pugh Class B or C).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:Denosumab group

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

安慰剂比较:Zolendronic acid group

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
6-metre walk
大体时间:From enrollment to the end of treatment at 52 weeks

The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as <1.0m/s.

From enrollment to the end of treatment at 52 weeks
5-time chair stand test
大体时间:From enrollment to the end of treatment at 8 weeks

The time to rise from a chair 5 times is recorded. The cut-off for is taken at >=12 seconds.

From enrollment to the end of treatment at 8 weeks
Appendicular skeletal muscle mass (ASM)
大体时间:From enrollment to the end of treatment at 52 weeks

Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is < 7 kg/m2 for men and 5.4 kg/m2 for women.

From enrollment to the end of treatment at 52 weeks
Handgrip strength
大体时间:From enrollment to the end of treatment at 52 weeks

Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is < 28kg, and female is <18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction

From enrollment to the end of treatment at 52 weeks
Quadriceps muscle strength
大体时间:From enrollment to the end of treatment at 52 weeks

Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation

From enrollment to the end of treatment at 52 weeks
Balancing ability
大体时间:From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%).

From enrollment to the end of treatment at 52 weeks
Balancing ability
大体时间:From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s)

From enrollment to the end of treatment at 52 weeks
Balancing ability
大体时间:From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%)

From enrollment to the end of treatment at 52 weeks
Balancing ability
大体时间:From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%)

From enrollment to the end of treatment at 52 weeks
Balancing ability
大体时间:From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s)

From enrollment to the end of treatment at 52 weeks

次要结果测量

结果测量
措施说明
大体时间
Falls
大体时间:From enrollment to the end of treatment at 52 weeks

To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year

From enrollment to the end of treatment at 52 weeks
Fracture
大体时间:From enrollment to the end of treatment at 52 weeks

Assess occurrence of a fracture within a year of study period.

From enrollment to the end of treatment at 52 weeks
Quality of life Short Form-36 (SF-36)
大体时间:From enrollment to the end of treatment at 52 weeks

The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life.

From enrollment to the end of treatment at 52 weeks
Physical activity scale for elderly (PASE)
大体时间:From enrollment to the end of treatment at 52 weeks

It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity

From enrollment to the end of treatment at 52 weeks
Food frequency questionnaire
大体时间:From enrollment to the end of treatment at 52 weeks

Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong.

From enrollment to the end of treatment at 52 weeks
Hospital admissions
大体时间:From enrollment to the end of treatment at 52 weeks

Number and cause of emergency hospital admission within 1 year of study period are documented.

From enrollment to the end of treatment at 52 weeks
Mortality
大体时间:From enrollment to the end of treatment at 52 weeks

Mortality within 1-year of study period is documented.

From enrollment to the end of treatment at 52 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月9日

初级完成 (估计的)

2027年4月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2024年9月15日

首先提交符合 QC 标准的

2024年10月13日

首次发布 (实际的)

2024年10月16日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅